ライフサイエンスコーパス: survivor

1 , and 6 median organ support-free days among survivors).

2 and early-adolescent and young adult cancer survivors.

3 and increased days free of ventilation among survivors.

4 was reported by 73% (95% CI, 70% to 75%) of survivors.

5 ng-term cognitive outcomes in severe malaria survivors.

6 epatoblastoma (16.2%; 95% CI, 8.6% to 26.0%) survivors.

7 (DLBCL) have led to an increasing number of survivors.

8 ena cavae (IVC), and higher heart rates than survivors.

9 l dependence (Barthel Index [BI] < 15) among survivors.

10 is and reduce the quality of life for cancer survivors.

11 lp improve HNC complications and QOL for HNC survivors.

12 reflecting ongoing HIV treatment costs among survivors.

13 ic outcome in out-of-hospital cardiac arrest survivors.

14 and a 4.6-fold higher risk in autologous BMT survivors.

15 s the major manifestation of COVID-19 in non-survivors.

16 gical deficits, suggesting hypoxic injury in survivors.

17 s may disrupt established genetic signals in survivors.

18 significantly differing in non-survivors and survivors.

19 cantly increasing quality of life for cancer survivors.

20 lar dysfunction and HF screening in low-risk survivors.

21 state-level analysis in 55,146 Covid-19 non-survivors.

22 ovided insufficient support when accessed by survivors.

23 gastrocnemius (MG) muscle in chronic stroke survivors.

24 onal digital mammography among breast cancer survivors.

25 verely impact auditory sensitivity in cancer survivors.

26 nce and efforts to prevent new cancers among survivors.

27 s significantly reduced among firearm injury survivors.

28 result in poor long-term outcome for stroke survivors.

29 rome observed in adult human surgical sepsis survivors.

30 P < 0.01] differed between survivors and non-survivors.

31 controls and a validation cohort of 92 SCAD survivors.

32 s common to both Nigerian and Sierra Leonean survivors.

33 omplications among Ebola virus disease (EVD) survivors.

34 ng adult survivors than for childhood cancer survivors.

35 opionate and tryptophan metabolites in elite-survivors.

36 CC2, and BRCA2, among others) in 508 (11.5%) survivors.

37 Of 177 eligible firearm injury survivors, 100 were successfully contacted and 63 comple

38 Among 1288 one-year survivors, 1135 (88.1%) had 3-month mRS >0, of whom 319

39 igher proportion of disability at 5 years in survivors (15/60.0% vs 9/31.0%, p=0.03).

40 Among survivors, 2 of 26 treated subjects (8%) and 0 of 13 con

41 hree cohorts were defined as follows: 1) ICU survivors; 2) one-year survivors reporting newly-acquire

42 Of 4,402 survivors, 495 (11.2%) developed 1,269 SNs.

43 Of 955 survivors, 54% were male, 66% were non-Hispanic White, a

44 in 63.8% (95% CI, 62.0% to 65.8%) of exposed survivors, 55.7% (95% CI, 53.2% to 58.2%) of unexposed s

45 eligible acute respiratory distress syndrome survivors (58%) participated (from 22 sites); their medi

46 Of 17 HSCT survivors, 7 are in complete remission and 5 are in good

47 We randomly selected severe trauma survivors (abbreviated injury score >=3 in at least 1 bo

48 or information form was developed to counsel survivors about the potential harms and benefits of surv

49 However, little is known about how commonly survivors acquire new medical devices during pediatric s

50 the frequency of cognitive impairment in ICU survivors across various time points after ICU discharge

51 Among high-risk survivors, adherence to COG breast, colorectal, skin, an

52 h in cancer-related disease, with only 8% of survivors after 5-year to the diagnosis.

53 Pertinently however long-term survivors after oesophagectomy demonstrated comparable t

54 A total of 1,464 female BMT survivors (allogeneic: n = 788; autologous: n = 676) par

55 Between 2014 and 2016, 11,337 survivors and 2,146 siblings in the Childhood Cancer Sur

56 for early adolescent and young adult cancer survivors and 5.6 [4.9-6.3] for childhood cancer survivo

57 with SARS-CoV-2 pneumonia (including 51 non-survivors and 59 discharged patients).

58 f subsequent breast cancer in allogeneic BMT survivors and a 4.6-fold higher risk in autologous BMT s

59 olerance is prevalent among childhood cancer survivors and associated with all-cause mortality.

60 Early-adolescent and young adult cancer survivors and childhood cancer survivors were both at gr

61 clinical utility in characterizing high-risk survivors and guiding intervention strategies.

62 verall SPC incidence and mortality among all survivors and highlight the importance of ongoing survei

63 ly analyzed the antibody repertoire in human survivors and identified a pair of potently neutralizing

64 elae (APNS) are common among civilian trauma survivors and military veterans.

65 st computed tomography (CT) findings between survivors and non-survivors with Coronavirus Disease 201

66 robust IgM and IgA responses evolved in both survivors and non-survivors with severe disease, non-sur

67 42% (IQR: 30-80), P < 0.01] differed between survivors and non-survivors.

68 nts with no initial respiratory distress) as survivors and nonsurvivors with 0.88 sensitivity and 0.8

69 ion is associated with better adherence, few survivors and PCPs have one.

70 ost-EVD complications occur in a majority of survivors and remain present more than 4 years after acu

71 s of clinical trials of adult cardiac arrest survivors and supported this P-COSCA initiative (Pediatr

72 nly parameter significantly differing in non-survivors and survivors.

73 riant genetic testing among a cohort of SCAD survivors and to identify genes or gene sets that have a

74 rus-specific T cell responses in Lassa fever survivors and vaccinated individuals as well as for desi

75 ivors and 5.6 [4.9-6.3] for childhood cancer survivors), and at increased risk of developing grade 3-

76 55.7% (95% CI, 53.2% to 58.2%) of unexposed survivors, and 26.3% (95% CI, 24.0% to 28.3%) of control

77 nd alkylating agents in non-chest irradiated survivors, and the effects of ovarian function on breast

78 Among survivors, anticoagulation use was associated with longe

79 Childhood cancer survivors are at elevated risk for requiring HAD, which

80 Young cancer survivors are at increased risk for morbidities related

81 Offspring of trauma survivors are more likely to develop PTSD, mood, and anx

82 ildren's Oncology Group (COG) guidelines for survivors at high risk for second malignant neoplasms or

83 We identified factors characterizing survivors at risk for not reporting receipt of a health

84 s the foremost cause of death globally, with survivors at risk for subsequent heart failure.

85 difference of good neurologic outcome among survivors between the two treatment arms (493/1,142 [43%

86 limit generalizability of our findings; and survivor bias related to the cohort age, which may resul

87 erm cognitive impairment is common among ICU survivors, but its natural history remains unclear.

88 ired between HSCT and conventionally treated survivors, but poorer in both groups compared with nonca

89 novel interdisciplinary care process for ICU survivor care and their primary family caregivers, and a

90 Our ICU survivor care process results in decreased mortality and

91 Readmission for ICU survivor care versus usual care: at 30 days (10.4% vs 26

92 Longitudinal design with 223 stroke survivor-care partner dyads enrolled at survivor dischar

93 depressive symptomatology and QOL in stroke survivor-care partner dyads.

94 pression and quality of life (QOL) in stroke survivor-care partner dyads.

95 ealth care delivery resources to form an ICU survivor clinic care process and compare this new proces

96 mpared to the non-paretic side on our stroke survivor cohort.

97 1.9 to 4.0; P < .001), and decreased parent-survivor communication regarding HPV vaccination (OR, 1.

98 ies and tumor resection as well as to cancer survivors could eliminate relapse causing dormant cells

99 lthough in-hospital mortality was 9%, 35% of survivors demonstrated significant, health-related quali

100 ty rate and a high rate of complications for survivors, despite modern medical advances.

101 Background Among breast cancer survivors, detecting a breast cancer when it is asymptom

102 t cancer (aged 15-20 years at diagnosis) and survivors diagnosed at age younger than 15 years (matche

103 Elevated breast cancer risk was based on survivors diagnosed with childhood cancer between 1970 a

104 roke survivor-care partner dyads enrolled at survivor discharge from rehabilitation hospitals.

105 Here we report that F(1) survivors due to primary-site deletions and indels occur

106 Among survivors, early IFN-alpha2b was not associated with hos

107 that compared with noncancer controls, HSCT survivors endorsed a significantly higher symptom preval

108 sing mortality in PICUs, a growing number of survivors experience long-lasting physical impairments.

109 amined prevalence of exercise intolerance in survivors exposed or not to cardiotoxic therapy, and ass

110 Survivors exposed to cranial radiation, pelvic radiation

111 At a median survivor follow-up of 33 months (range, 2-53), 11 patien

112 Survivors following very premature birth (i.e., <= 32 we

113 ongitudinal antibody repertoires of an Ebola survivor from disease onset.

114 cond-site suppressors resulting in heritable survivors from 1.2 million zygotes.

115 QOL evaluation was conducted in survivors from a large cohort of patients with caustic i

116 and IgM present in the blood of Lassa fever survivors from Nigeria or Sierra Leone exhibited substan

117 y common T cell epitopes between Lassa fever survivors from Sierra Leone and Nigeria, where distinct

118 5-year survivors from the CCSS cohort were included if they wer

119 We sequenced a cohort of 384 SCAD survivors from the United Kingdom, alongside 13 722 UK B

120 ntly collected prospective cohorts of trauma survivors from two level 1 emergency trauma centers, whi

121 ior in HTS, we assessed an existing binomial survivor function (BSF) model of "frequent hitters" usin

122 Survivors generally undergo a workup to identify the cau

123 more predominant in non-survivor group than survivor group (39.0% vs. 12.0%, p < 0.001).

124 y-paving pattern was more predominant in non-survivor group than survivor group (39.0% vs. 12.0%, p <

125 From the prediction of curve estimation, in survivor group total CT score increased in the first 20

126 mains and HRQOL (all P > .05); however, HSCT survivors had a significantly higher cumulative prevalen

127 HSCT and conventionally treated survivors had a similar prevalence of all symptom domain

128 Early-adolescent and young adult cancer survivors had higher risks of mortality and severe and l

129 Early-adolescent and young adult survivors had lower SMRs for death from health-related c

130 Over 70% of survivors had proteinuria on long-term follow-up.

131 outcome (177 +/- 160 cells; P = .004), while survivors had similar CD4 cell count at baseline, regard

132 These "elite-survivors" harbored distinct gut microbiota that develop

133 longer duration of mechanical ventilation in survivors (hazard ratio, 0.64; 95% CI, 0.49-0.82; p < 0.

134 lores associations between colorectal cancer survivors' healthcare experiences and quality of life.

135 mproving social participation in post-stroke survivors, however it is unclear what the most effective

136 ns, conducted separately for CNS and non-CNS survivors, identified associations between PA consistenc

137 of hematopoietic cell transplant, and among survivors immunocompromised patients have shorter median

138 ng psycho-social care to cancer patients and survivors in Ireland.

139 The participating survivors in the two groups did not differ regarding bas

140 urvivors of DLBCL compared with other cancer survivors, including significantly and consistently elev

141 A survivor information form was developed to counsel survi

142 a world where cancer is prevented and every survivor is healthy.

143 The number of critical care survivors is growing, but their long-term outcomes and r

144 ening strategies for IGHG high- and low-risk survivors is needed, including careful reconsideration o

145 In ICH survivors, lobar ICH location was associated with a high

146 We followed all survivors longitudinally and recorded subsequent blood c

147 Survivors (mean age +/- standard deviation [SD], 35.6 +/

148 Among 1 537 101 survivors (mean age, 60.4 years; 48.8% women), 156 442 S

149 CI 5.5-6.2) and among 5804 childhood cancer survivors (median age 34 years; 27-42), it was 6.2 (5.8-

150 Among 5804 early-adolescent and young adult survivors (median age 42 years, IQR 34-50) the SMR compa

151 At day 15, survivor mice completed a battery of cognitive and behav

152 7.7% (95% CI, 15.8-19.8%; n = 242) in 1-year survivors (n = 1,368).

153 number was significantly lower in transplant survivors (n = 14) compared with posttransplant disease

154 Compared with matched MVC survivors (n = 255), firearm injury survivors were signi

155 Cancer survivors (n = 50) and non-cancer participants (n = 50)

156 Serum or plasma from Nigerian Lassa fever survivors neutralized LASV pseudoviruses expressing line

157 Across 12 studies, compared with septic survivors, nonsurvivors had significantly increased expr

158 No association was observed among survivors not exposed to alkylating agents included in t

159 y in determining an individual's status as a survivor of EVD.

160 monoclonal antibodies (mAbs) isolated from a survivor of natural EEEV infection with potent (<20 pM)

161 k of subsequent primary cancers (SPCs) among survivors of adult-onset cancers are limited.

162 Among survivors of adult-onset cancers in the United States, s

163 ned using whole-genome sequencing data among survivors of African ancestry, first based on ejection f

164 In survivors of African ancestry, rs6689879*C showed a 5.43

165 F reduction = 4.2%; P = 2.8 x 10(-8)) in 246 survivors of African ancestry, which was successfully re

166 The cohort included 6,778 survivors of AYA cancer and 87,737 persons without a his

167 of developing comorbidities is increased in survivors of AYA cancer compared with the general popula

168 Survivors of AYA cancer had a 2- to 3-fold increased ris

169 Forty percent of survivors of AYA cancer had multiple (>= 2) comorbiditie

170 d immunocompromised persons.Among the 30-day survivors of brain abscess (median follow-up 7.6 years [

171 The majority of survivors of breast cancer and lymphoma who have receive

172 ut cancer was individually matched (13:1) to survivors of cancer on age, sex, and calendar year.

173 Among survivors of cancer, significant associations between ch

174 and selected comorbidities were examined for survivors of cancer.

175 port early coronary angiography for comatose survivors of cardiac arrest without ST elevation.

176 oangiopathy and neurocognitive impairment in survivors of childhood acute lymphoblastic leukemia.

177 ons, and neurocognitive outcomes among 6,148 survivors of childhood ALL (median age, 27.9 years; rang

178 Survivors of childhood cancer treated with anthracycline

179 Adult survivors of childhood cancer who report more consistent

180 red spermatogenesis among nonirradiated male survivors of childhood cancer, but there is substantial

181 f all symptom domains (all P < .05) in adult survivors of childhood cancer, except for pain and anxie

182 general populations, is not well studied in survivors of childhood cancer.

183 Survivors of childhood hematologic malignancies (HSCT N

184 Poor patient-reported outcomes in all survivors of childhood hematologic malignancies correlat

185 ncer surveillance recommendations for female survivors of childhood, adolescent, and young adult canc

186 Survivors of CNS cancers (52.8 +/- 0.3) also reported po

187 Survivors of CNS tumors (9.5%; 95% CI, 5.2% to 13.8%) an

188 ed late mortality and SMN risks among 5-year survivors of contemporary, standard-risk childhood ALL a

189 l ventilation on cognitive function in adult survivors of critical illness.

190 Frailty is common among survivors of critical illness.

191 with disability and cognitive impairment in survivors of critical illness.

192 (IRRs) for many immune-related conditions in survivors of DLBCL compared with other cancer survivors,

193 -up to demonstrate impaired immune health in survivors of DLBCL.

194 We evaluated outcomes among survivors of early-adolescent and young adult cancer (ag

195 all-cause and cause-specific mortality among survivors of early-adolescent and young adult cancer.

196 ebolavirus, may persist in the semen of male survivors of Ebola Virus Disease (EVD).

197 tdiagnosis physical activity and survival in survivors of endometrial cancer by physical activity dom

198 sis, is associated with improved survival in survivors of endometrial cancer.

199 , which was successfully replicated in 1,645 survivors of European ancestry but with attenuated magni

200 Similar results were observed in survivors of European ancestry, albeit with reduced magn

201 licated in two independent samples of SJLIFE survivors of European ancestry, including 34 nonirradiat

202 nderstanding of EVD and viral persistence in survivors of EVD, resulting in new strategies toward pre

203 fication system for the increasing number of survivors of extreme prematurity suffering the most seve

204 ntal health screening, and interventions for survivors of firearm violence.

205 However, survivors of heritable retinoblastoma have a significant

206 s of visual impairment among aging long-term survivors of HIV.

207 ography and magnetic resonance imaging among survivors of Hodgkin lymphoma.

208 and fifty-three female adolescent and adult survivors of interpersonal violence and non-trauma-expos

209 s species to expand after extinction events, survivors of intervals with net species loss expanded as

210 were identified (athletes, n = 10; long-term survivors of moderate or severe TBI, n = 4) from the Gla

211 Targeted temperature management in comatose survivors of out-of-hospital cardiac arrest.

212 and brain structure is feasible in long-term survivors of pediatric brain tumors and that metformin i

213 nducted (ClinicalTrials.gov, NCT02040376) in survivors of pediatric brain tumors who had been treated

214 Blood, Yen and colleagues report that adult survivors of pediatric hematologic malignancies have hig

215 Patient-reported outcomes among survivors of pediatric hematopoietic stem cell transplan

216 When prognosticating for survivors of severe COVID-19, clinicians should consider

217 e morbidity and mortality among contemporary survivors of standard-risk ALL, represented by 90sSR.

218 We conducted a study of male survivors of the 2014-2016 EVD outbreak in Liberia and e

219 Chronic neurodegeneration in survivors of traumatic brain injury (TBI) is a major cau

220 genetic makeups of wild survivors versus non-survivors of WNS, and found significant shifts in allele

221 ays/total days with ESD; n=5891), and stroke survivor outcome (modified Rankin scale at ESD discharge

222 alization among nonsurgical critical illness survivors over the past decade.

223 tion-based cohort of 1-year ischaemic stroke survivors (Oxford Vascular Study; 2002-2014), we examine

224 For high-risk survivors, PCP possession of a SCP was associated only w

225 Extracorporeal membrane oxygenation survivors' physical quality of life was worse than popul

226 ortive care have resulted in a growing adult survivor population.

227 Moreover, being a cancer survivor, predicted more barriers to receiving health ca

228 n care partner depressive symptomatology and survivor psychological QOL (B=0.03, P<0.05) and moderate

229 the development of interventions to improve survivors' quality of life in the context of healthcare.

230 Survivors relocated to TH appeared to be at an increased

231 Childhood cancer survivors reported a higher prevalence of frailty compar

232 ine (mean 408 days from acute EVD), 75.5% of survivors reported at least 1 new cardinal symptom since

233 ed as follows: 1) ICU survivors; 2) one-year survivors reporting newly-acquired chronic pain; and (3)

234 QALY gained for all strategies for low-risk survivors, representing approximately 40% of those for w

235 ementary DNA methylation data in a subset of survivors revealed that treatment-related methylation pa

236 that can preserve bone and improve a cancer survivor's quality of life.

237 The survivor's spirituality significantly moderated the asso

238 Although survivor SCP possession is associated with better adhere

239 For high-risk survivors, SCP possession was associated with increased

240 Conclusion Among breast cancer survivors, screening with digital breast tomosynthesis l

241 s and non-survivors with severe disease, non-survivors showed attenuated IgG responses, accompanied b

242 e reported that adult offspring of Holocaust survivors showed lower methylation of FK506 binding prot

243 d with longitudinal lung function decline in survivors, smoking history, or current smoking status.

244 of cancer therapy) than did childhood cancer survivors (SMR 4.8 [95% CI 4.4-5.1] vs 6.8 [6.2-7.4]), w

245 d to evaluate the association between cancer survivor status and risk of developing each comorbidity.

246 anadian participants in the Childhood Cancer Survivor Study (CCSS) cohort and validated in the St Jud

247 s and 2,146 siblings in the Childhood Cancer Survivor Study completed a survey ascertaining adherence

248 dependent nonoverlapping cohort from the BMT Survivor Study with self-report of learning/memory probl

249 ted in the ongoing longitudinal Liberian EVD Survivor Study.

250 ute cardiovascular events and cardiac arrest survivors, testing for primary and secondary disease-cau

251 e lower for early-adolescent and young adult survivors than for childhood cancer survivors.

252 arbitrary perfusion unit/s) were greater in survivors than in nonsurvivors.

253 Capillary refill time was shorter in survivors than in nonsurvivors; peripheral perfusion ind

254 Cancer survivors that were affected by HM reported increased ba

255 ses, cleared the tumor, leading to long-term survivors that were then resistant to the formation of n

256 urrent global standard assessment of torture survivors, the UNIP, to increase the accuracy of pain di

257 We analyzed the differences between survivors to hospital discharge and those who died.

258 ges to both kill bacterial cells and 'steer' survivors towards resistant but more compromised phenoty

259 an ancestry, including 34 nonirradiated male survivors treated with 0 < CED < 4,000 mg/m(2) (P = 3.1

260 hy and breast magnetic resonance imaging for survivors treated with 10 Gy or greater chest radiation

261 d for routine breast cancer surveillance for survivors treated with any type of anthracyclines in the

262 4,000 mg/m(2) (P = 3.1 x 10(-4)) and 24 male survivors treated with CED >=4,000 mg/m(2) and radiother

263 ing and 3 T brain MRI's were obtained in 101 survivors treated with cranial radiation.

264 Among the 49 survivors treated with ECMO, 32 who had been treated at

265 and the relative fecundity/fertility of the survivors, varied from a <4% positive effect of the symb

266 We compared the genetic makeups of wild survivors versus non-survivors of WNS, and found signifi

267 Median follow-up among survivors was 11 years.

268 utoff on Aug 6, 2019, median follow-up among survivors was 13.0 months (IQR 11.7-23.5).

269 The cumulative incidence of HAD among survivors was 2.1% (95% CI, 1.7% to 2.5%) at 20 years an

270 Status of ICU survivors was assess until 1 year after discharge.

271 nd vegetable consumption among breast cancer survivors was not associated with breast cancer-specific

272 e supporting routine testing of asymptomatic survivors was not identified.

273 sess the risk of ESKD among childhood cancer survivors, we conducted a nationwide, population-based,

274 tudying the largest sequenced cohort of SCAD survivors, we demonstrate that, based on current knowled

275 At survey participation, survivors were an average age (+/- standard deviation) o

276 adult cancer survivors and childhood cancer survivors were both at greater risk of developing severe

277 from the natal stream as fry or smolts, the survivors were dominated by the rare few that left at in

278 Survivors were enumerated immediately after treatment.

279 The fractions of long-term cancer survivors were estimated to be 47.4% and 18.0% in the la

280 late life (1998), and then 744 dementia-free survivors were followed further into late life (2005 to

281 All survivors were off immunoglobulin replacement and had pr

282 t year, 1,290 of 2,212 (58.3%) index episode survivors were rehospitalized.

283 ched MVC survivors (n = 255), firearm injury survivors were significantly more likely to have daily p

284 Survivors were significantly younger (40.5 years vs. 53.

285 85 (182-193) days after randomization, 2,492 survivors were surveyed and reported similar quality of

286 edically fragile populations, such as cancer survivors, were significantly affected.

287 the neutralising ability of plasma from EVD survivors, when compared to results from a live EBOV neu

288 The number of cancer survivors who develop new cancers is projected to increa

289 ng EVD survival were assessed in the 326 EVD survivors who participated in the ongoing longitudinal L

290 Survivors who were living with active malignant disease

291 al antibodies (mAbs) from B cells of a human survivor with previous naturally acquired MARV infection

292 responses in 37 Sierra Leonean EBOV disease survivors with (n = 19) or without (n = 18) sequelae of

293 aphy (CT) findings between survivors and non-survivors with Coronavirus Disease 2019 (COVID-19).

294 Survivors with impairments may require referral to train

295 bility, affecting up to two thirds of stroke survivors with no available therapeutic options.

296 ewly-acquired chronic pain; and (3) one-year survivors with pain who lived within 50 km from the stud

297 Survivors with sequelae had a significantly higher EBOV-

298 responses evolved in both survivors and non-survivors with severe disease, non-survivors showed atte

299 led a prospective, multicenter cohort of ICU survivors with shock or respiratory failure from surgica

300 reast cancer treatment can negatively affect survivors' work ability.